BioCurex Begins Development of Unique 'POINT-OF-CARE' Test For Cancer
BioCurex Inc. announced that is has started development of a 'point-of-care' RECAF test which would be available for use at the doctor's office rather than in a laboratory setting. During the past two quarters, the Company has been engaged in converting its original radioactive-labeled RECAF blood test for cancer detection into a non-radioactive, colorimetric assay. The information gathered in the format conversion strongly supports the feasibility of a 'point-of-care' blood test for cancer detection.
The RECAF 'point-of-care' system would be targeted at physicians who either suspect a malignancy at a patient's first visit or are monitoring a patient after cancer treatment. The doctor would carry out the test in their office in a matter of minutes while examining the patient. Given the necessarily lower accuracy of a 'point-of-care' test, the device will not 'cannibalize' sales of the more precise clinical laboratory tests. Rather, it will orient the physician in the diagnostic procedure and according to the reading, prompt the request of a more accurate test from a laboratory, such as the Company's RECAF serum test. This is similar to the principle whereby a more sophisticated test is utilized to confirm the results of the point-of-care pregnancy tests available in drug stores.
Most read news
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Chromos and AviGenics sign licensing deal - ACE System extracts value from transgenics field
SR Pharma plc announces IND for a 2nd siRNA therapeutic based on its unique proprietary chemistry
Nanoparticle drug reverses Parkinson's-like symptoms in rats

50 years of image analysis - A room full of electronics - from QTM A to LAS 4.2
TxCell achieves positive results for Col-Treg in a model of autoimmune uveitis
Antisoma initiates phase IIb trial of AS1411 in acute myeloid leukaemia
ITI Life Sciences Seeks to Fund Innovative R&D Programme in Synthetic Biology, focusing on Gene & Genome Synthesis and Assembly
GE Healthcare and BAC start collaboration in biopharmaceutical purification
CuraGen and TopoTarget Initiate Phase Ib Clinical Trial with PXD101 for Advanced Colorectal Cancer - Proof-of-Concept Trial Evaluating PXD101 Combination Therapy with 5- fluorouracil for Advanced Solid Tumors and Colorectal Cancer
Vernalis extends cancer research collaboration with Novartis Institutes for BioMedical Research - Joint research and development programme on Hsp90, a target implicated in a number of different cancers - Vernalis to receive a $1.5 million signature fee - Novartis to make an investment in new Vernalis shares of approximately ?5 million
Kiadis Pharma receives two orphan drug designations for Reviroc from the FDA
